Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
大藥企是否有望接管大麻股？美國已有3家公司掌控了10份處方藥中的8份
The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical questions about the future of the cannabis industry, especially if cannabis is federally legalized.
美國聯邦貿易委員會（FTC）最近強調了由於市場整合，藥房福利經理（PBM）對藥品價格的重大影響。這種趨勢對大麻行業的未來提出了關鍵問題，尤其是在大麻獲得聯邦合法化的情況下。
The Role Of PBMs And Market Influence
PBM的作用和市場影響力
PBMs, such as UnitedHealth Group (NYSE:UNH)'s Optum, CVS Health (NYSE:CVS)'s CVS Caremark and Cigna (NYSE:CI)'s Express Scripts, negotiate discounts, create medication lists covered by insurance and reimburse pharmacies.
PBM，例如UnitedHealth Group（紐約證券交易所代碼：UNH）的Optum、CVS Health（紐約證券交易所代碼：CVS）的CVS Caremark和信諾（紐約證券交易所代碼：CI）的Express Scripts等PBM就折扣進行談判，制定保險承保的藥物清單，並報銷藥房。
The FTC's interim report revealed that these three PBMs manage 79% of U.S. prescription drug claims...
聯邦貿易委員會的中期報告顯示，這三...
登入免費觀看全文
登入/註冊